Alpha DNA Investment Management’s MaxLinear MXL Stock Holding History

Alpha DNA Investment Management’s Portfolio MXL Stock Details MXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-27,891	Closed	-$946K	–	184
2022 Q2	$946K	Buy	27,891 +8,424	+43%	+$353K	0.81%	80
2022 Q1	$1.14M	Sell	19,467 -1,858	-9%	-$113K	0.8%	96
2021 Q4	$1.61M	Sell	21,325 -6,559	-24%	-$420K	1.01%	40
2021 Q3	$1.37M	Sell	27,884 -8,427	-23%	-$408K	0.93%	75
2021 Q2	$1.54M	Buy	36,311 +18,779	+107%	+$700K	1.05%	29
2021 Q1	$597K	Sell	17,532 -7,408	-30%	-$264K	0.69%	80
2020 Q4	$952K	Buy	+24,940	New	+$724K	1.01%	24

Other funds holding MXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return

Alpha DNA Investment Management's MXL Position: Q3 2022 in Review

Alpha DNA Investment Management sold out of MaxLinear (MXL) in Q3 2022, closing a stake of 27,891 shares — an estimated $946K sold.

Alpha DNA Investment Management first reported a position in MXL in Q4 2020 and held it in 7 quarters. The position peaked at $1.61M in Q4 2021. 279 funds tracked by Wall St. Rank hold MXL as of Q3 2022.

Alpha DNA Investment Management reported no remaining MaxLinear position as of Q3 2022 after selling out during the quarter.
Alpha DNA Investment Management sold 27,891 MaxLinear shares in Q3 2022, an estimated $946K.
Alpha DNA Investment Management first reported a position in MaxLinear in Q4 2020 and held it in 7 quarters.
Alpha DNA Investment Management's MaxLinear position peaked at $1.61M in Q4 2021.
279 funds tracked by Wall St. Rank held MaxLinear as of Q3 2022.

Based on Alpha DNA Investment Management's 13F filing for Q3 2022, filed 15 Nov 2022.